The primary endpoint analysis showed a dose-dependent increase in total sleep time from baseline on day one.
After notching a phase 2 trial win, Idorsia’s insomnia med Quviviq (daridorexant) is one step closer to potentially becoming a first-in-class treatment for children. | After notching a phase 2 trial ...
New developments tonight in a controversy rocking the Jacksonville North Pulaski School District. A former elementary school principal is out of a job, and her Longtime Stuttgart journalist Bill Shrum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results